The U.S. Food and Drug Administration (FDA) has recorded the status of product THEOLIXIR under application number ANDA084559. THEOLIXIR is an oral elixir (route: ORAL) marketed by sponsor PANRAY. The product contains the active ingredient THEOPHYLLINE at a strength of 80 mg per 15 mL. According to the FDA filing, the marketing status of THEOLIXIR is listed as discontinued. No reference drug or reference standard is associated with this filing.
Cập nhật pháp chế25 thg 9, 2026•1 phút đọc
FDA Marks PANRAY's THEOLIXIR Oral Elixir as Discontinued (ANDA084559)
The FDA’s ANDA084559 filing shows PANRAY’s oral elixir THEOLIXIR, containing THEOPHYLLINE 80MG/15ML, is listed as discontinued.
Tổng hợp bởi đội ngũ PharmaCountry · Nguồn: FDA.gov
Đánh giá
(0)
(0)
(0)
(0)
(0)
Bài viết khác
Xem tất cả bài viếtNghiên cứu & Báo cáo
Global Finished Dosage Manufacturing Landscape 2026
5 thg 10, 2026
Cập nhật pháp chếKorea Korus hit with 1‑month manufacturing suspension over missing post‑marketing safety test
28 thg 9, 2026
Phân tíchPharma distributors set delivery cut‑offs ahead of Chuseok holiday (Sep 21‑23)
28 thg 9, 2026
Để lại đánh giá